EODData

MEMBERSHIP REGISTER LOG IN

FRA, 12X1: Anavex Life Sciences Corp

26 Jan 2026
LAST:

4.311

CHANGE:
 0.05		OPEN:
4.311		HIGH:
4.311		ASK:
0.000		VOLUME:
6.0K
CHG(%):
1.21		PREV:
4.364		LOW:
4.311		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Jan 264.3114.3114.3114.3116.0K
23 Jan 264.3644.3644.3644.3646.0K
22 Jan 264.4174.4174.4174.4176.0K
21 Jan 264.2474.2474.2474.2476.0K
20 Jan 264.0534.0534.0534.0536.0K
19 Jan 264.1824.1824.1824.1826.0K
16 Jan 264.0634.0634.0634.0636.0K
15 Jan 264.0614.0614.0614.0616.0K
14 Jan 264.0324.0324.0324.0326.0K
13 Jan 263.5573.5573.5573.5576.0K

PROFILE

Name:Anavex Life Sciences Corp
About:Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:630 5th Avenue, New York, NY, United States, 10111
Website:https://www.anavex.com
ISIN:US0327973006
LEI:549300K1I5L8COCQ8W36

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.71 
Forward P/E:-4.68 
PEG Ratio:-4.68 
Price to Book:3.32 
Return on Assets:-0.27 
Return on Equity:-0.43 
Shares:85.89M 
Market Cap:370.29M 

TECHNICAL INDICATORS

MA5:4.280.8%
MA10:4.134.4%
MA20:3.7016.6%
MA50:3.5720.7%
MA100:5.5528.6%
MA200:6.8358.5%
STO9:72.47
STO14:90.42 
RSI14:69.58 
WPR14:-9.58 
MTM14:1.00
ROC14:0.30 
ATR:0.14 
Week High:4.422.5%
Week Low:4.056.4%
Month High:4.422.5%
Month Low:2.8758.5%
Year High:11.49166.5%
Year Low:2.2690.7%
Volatility:28.87